Global News and Digital Insights
for the Healthcare Industry

UCB’s Fintepla nabs recommendations from NICE for Dravet Syndrome

National Institute for Healthcare Excellence (NICE) has recommended Fintepla, an oral drug manufactured by the biopharmaceutical firm UCB, for Dravet Syndrome. In the announcement, the pharma company informed that the final nod from NICE will enable them to make the treatment available as an additional therapy for patients aged two years or above. Dravet syndrome is a form of epilepsy that affects infants and is a lifelong partner. Fintepla will be used to treat the symptoms of this particular syndrome. While Dravet syndrome can affect a person’s life, it puts their life at risk as well.

Read More from PharmaTimes

Share on facebook
Share on twitter
Share on linkedin